Compare SO & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SO | GLSI |
|---|---|---|
| Founded | 1946 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.2B | 123.9M |
| IPO Year | N/A | 2020 |
| Metric | SO | GLSI |
|---|---|---|
| Price | $94.63 | $26.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 1 |
| Target Price | ★ $94.03 | $50.00 |
| AVG Volume (30 Days) | ★ 6.3M | 639.1K |
| Earning Date | 02-19-2026 | 11-14-2025 |
| Dividend Yield | ★ 3.20% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.02 | N/A |
| Revenue | ★ $28,913,000,000.00 | N/A |
| Revenue This Year | $10.02 | N/A |
| Revenue Next Year | $5.19 | N/A |
| P/E Ratio | $23.01 | ★ N/A |
| Revenue Growth | ★ 9.40 | N/A |
| 52 Week Low | $83.09 | $7.78 |
| 52 Week High | $100.84 | $34.10 |
| Indicator | SO | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 66.74 | 50.41 |
| Support Level | $88.84 | $25.68 |
| Resistance Level | $93.26 | $30.13 |
| Average True Range (ATR) | 1.50 | 3.14 |
| MACD | 0.32 | -0.80 |
| Stochastic Oscillator | 89.79 | 20.84 |
Southern is one of the largest utilities in the US. The company serves 9 million customers with vertically integrated electric utilities in three states and natural gas distribution utilities in four states. It owns 44 gigawatts of rate-regulated generating capacity, primarily for serving customers in Georgia, Alabama, and Mississippi. Subsidiary Southern Power owns 13 gigawatts of natural gas generation and renewable energy across the US and sells the electricity primarily under long-term contracts.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.